Why Pharming Group N.V.’s (PHAR) Stock Is Up 6.25%
As of Monday, October 26, Pharming Group N.V.’s PHAR share price has surged by 6.25%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Commentary & Analysis
Why Pharming Group N.V.’s (PHAR) Stock Is Up 6.28%
As of Friday, October 23, Pharming Group N.V.’s PHAR share price has surged by 6.28%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Pharming Group N.V.’s (PHAR) Stock Is Up 10.05%
As of Thursday, October 22, Pharming Group N.V.’s PHAR share price has surged by 10.05%, which has investors questioning if this is right time to sell.Michael Rose
Why Pharming Group N.V.’s (PHAR) Stock Is Up 11.92%
As of Thursday, October 22, Pharming Group N.V.’s PHAR share price has surged by 11.92%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Pharming Group N.V.’s (PHAR) Stock Is Up 5.16%
As of Tuesday, October 20, Pharming Group N.V.’s PHAR share price has surged by 5.16%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | PHAR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $856.4 | $232.8 | 44% |
|
| Shares Out (Mil) | 666.1 | 53.4 | 91% |
|
| Institutional Ownership | 92.6% | 92.9% | 61% |
|
| Float (Mil) | 696.6 | 41.2 | 88% |
|
| Beta | 0.07 | 0.96 | 8% |
|
| Avg Daily Volume (000s) | 19 | 490 | 21% |
|
| Price Change (52-week) |
(9.3%) | 48.2% | 45% |
|
| Growth | PHAR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 12.1% | 12.8% | 66% |
|
| Net Income (5yr) | (40.1%) | (10.1%) | 9% |
|
| EPS (5yr) | (40.8%) | 15.8% | 5 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (9.1%) | (15.7%) | 58% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | $0.070 | $0.265 | $0.385 | |
| Month Ago EPS | $0.270 | $0.460 | $0.307 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.107 | $0.230 | $0.066 | |
| Year/Year Chg | 3,400% | 6,525% | 8,900% | |
| Financials | PHAR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $367 | $37 | 38% |
|
| Net Income (TTM) (Mil) | $9 | ($44) | 45% |
|
| EPS (TTM) | $0.013 | ($1.600) | 40% |
|
| Operating Cash Flow (TTM) (Mil) | $35 | ($33) | 44% |
|
| Net Cash Flow (TTM) (Mil) | ($60) | $2 | 19% |
|
| Long-Term Debt (Q1) (Mil) | $104 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | $927 | $174 | 40% |
|
| Valuation | PHAR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 31.82 | 2.22 | 97% |
|
| P/E | 930.0 | 20.8 | 100% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PHAR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 87.7% | 66.9% | 93% |
|
| Net Margin | 6.3% | (75.3%) | 52% |
|
| ROA | 2.1% | (47.3%) | 56% |
|
| ROE | 3.8% | (53.3%) | 41% |
|
| Liabilities to Assets | 42.2% | 29.4% | 33% |
|
| F-Score | 7 | 2 | 82% |
|
Pharming Group N.V. did not pass any screens on 10/28/2026.
